Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin. 2015

Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.

A 34-year-old man with 22q11.2 deletion syndrome (DiGeorge syndrome) concurrently suffered from myopathy and eosinophilic pneumonia shortly after receiving daptomycin (DAP) for right-sided infective endocarditis. The simultaneous occurrence of these phenomena in relation to DAP therapy has not been previously well described. An allergic reaction was suspected as a possible etiology of these DAP-related complications. This case highlights the need for close observation in order to detect both musculoskeletal and respiratory disorders from the start of DAP therapy. Physicians should pay more attention to this new drug, which is expected to be frequently used in various clinical settings.

UI MeSH Term Description Entries
D008297 Male Males
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D011657 Pulmonary Eosinophilia A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents. Eosinophilia, Pulmonary,Eosinophilic Pneumonia,Loeffler Syndrome,Pneumonia, Eosinophilic,Eosinophilias, Pulmonary,Pulmonary Eosinophilias,Simple Pulmonary Eosinophilia,Tropical Eosinophilic Pneumonia,Eosinophilic Pneumonia, Tropical,Eosinophilic Pneumonias,Eosinophilic Pneumonias, Tropical,Pneumonias, Eosinophilic,Pulmonary Eosinophilia, Simple,Simple Pulmonary Eosinophilias,Syndrome, Loeffler,Tropical Eosinophilic Pneumonias
D004062 DiGeorge Syndrome Congenital syndrome characterized by a wide spectrum of characteristics including the absence of the THYMUS and PARATHYROID GLANDS resulting in T-cell immunodeficiency, HYPOCALCEMIA, defects in the outflow tract of the heart, and craniofacial anomalies. Velocardiofacial Syndrome,22q11.2 Deletion Syndrome,22q11.2DS,Autosomal Dominant Opitz G-Bbb Syndrome,Catch22,Conotruncal Anomaly Face Syndrome,Conotruncal Anomaly Face Syndrome (CTAF),Deletion 22q11.2 Syndrome,DiGeorge Anomaly,DiGeorge Sequence,Familial Third and Fourth Pharyngeal Pouch Syndrome,Hypoplasia of Thymus and Parathyroids,Pharyngeal Pouch Syndrome,Sedlackova Syndrome,Shprintzen Syndrome,Shprintzen VCF Syndrome,Third and Fourth Pharyngeal Pouch Syndrome,Thymic Aplasia Syndrome,VCF Syndrome,Velo-Cardio-Facial Syndrome,Autosomal Dominant Opitz G Bbb Syndrome,Deletion Syndrome, 22q11.2,Syndrome, DiGeorge,Syndrome, Sedlackova,Syndrome, Shprintzen,Syndrome, VCF,Syndrome, Velo-Cardio-Facial,Syndrome, Velocardiofacial,Velo Cardio Facial Syndrome
D004697 Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides,Bacterial Endocarditis,Endocarditides, Bacterial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D017576 Daptomycin A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. Cubicin,Daptomycin, 9-L beta-Aspartic Acid,Deptomycin,LY-146032,Daptomycin, 9 L beta Aspartic Acid,LY 146032,LY146032

Related Publications

Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
April 2007, The Journal of infection,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
February 2024, Cureus,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
August 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
April 2024, JAAPA : official journal of the American Academy of Physician Assistants,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
February 2021, Cureus,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
June 2018, Cureus,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
October 2014, WMJ : official publication of the State Medical Society of Wisconsin,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
February 2022, Antibiotics (Basel, Switzerland),
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
October 2022, Cureus,
Hideharu Hagiya, and Kou Hasegawa, and Kikuko Asano, and Tomohiro Terasaka, and Kosuke Kimura, and Takahiro Nada, and Eri Nakamura, and Koichi Waseda, and Yoshihisa Hanayama, and Fumio Otsuka
January 2018, Respiratory medicine case reports,
Copied contents to your clipboard!